Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 7/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21781876 | 0.84 | MAP1LC3B (0.37) | FURINKMT2A | |
| SCHEMBL20800167 | 0.84 | KMT2A (0.42) | C3AR1FURINPRSS1POLBNOD1 | |
| SCHEMBL21781878 | 0.84 | MAP1LC3B (0.37) | FURINKMT2A | |
| SCHEMBL21781879 | 0.83 | MAP1LC3B (0.37) | FURINKMT2A | |
| SCHEMBL20800175 | 0.79 | GNPAT (0.49) | C3AR1FURINFOLH1POLBNOD1 | |
| SCHEMBL26223141 | 0.77 | C3AR1 (0.43) | C3AR1FURINPRSS1FOLH1POLB | |
| SCHEMBL21607789 | 0.77 | C3AR1 (0.43) | C3AR1FURINPRSS1FOLH1POLB | |
| SCHEMBL29485129 | 0.77 | NMT2 (0.43) | C3AR1FURINFOLH1CPB2POLB | |
| SCHEMBL19432348 | 0.76 | KMT2A (0.41) | FURINKMT2AITGB3ITGA2BEPHX2 | |
| SCHEMBL24193304 | 0.76 | C3AR1 (0.42) | C3AR1FURINPOLBNOD1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207420-B2 | Cytotoxin and conjugate, uses of same and preparation method therefor | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-12-28 | — | — | US | disclosed |
| US-20200179529-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207420-B2 | Cytotoxin and conjugate, uses of same and preparation method therefor | CD2, HAVCR2, CD4 | C3AR1 572/4885FURIN 676/4885PRSS1 860/4885 |
| US-20200179529-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR | CD2, HAVCR2, CD4 | C3AR1 572/4885FURIN 676/4885PRSS1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.